期刊
HEPATOLOGY COMMUNICATIONS
卷 5, 期 7, 页码 1138-1150出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1002/hep4.1745
关键词
-
资金
- Spanish Ministry of Science and Innovation [PID2019-103955RB-100]
The novel coronavirus SARS-CoV-2 has caused the global COVID-19 pandemic in a short period of time, with implications for individuals with underlying chronic liver disease who may face increased risk of adverse outcomes and liver damage.
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel coronavirus that causes coronavirus disease 19 (COVID-19), which has infected millions of people worldwide in only a few months. A minority, but significant number, of infected individuals require hospitalization and intensive care. From the start of this new virus pandemic, it was apparent that obese and/or diabetic individuals had a bad prognosis for COVID-19 progression, strongly suggesting an association between liver disease and severe COVID-19. Because chronic liver disease (CLD) is associated with immune dysregulation and inflammation, it is unsurprising that patients with CLD may carry a greater risk of adverse outcomes following SARS-CoV-2 infection. Initial COVID-19 data have also indicated that healthy infected individuals display abnormal liver function tests, suggesting a possible direct implication of SARS-CoV-2 in liver damage. Here we show that COVID-19 affects the liver metabolism and increases the morbidity and mortality of individuals with underlying CLD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据